We recently demonstrated that anti-CCL2 antibody treatment decreases the number of MAMs at the metastatic sites and reduces metastatic tumor burden in an experimental model of breast cancer lung metastasis [12]. This evidence concerns the gene CCL2 and breast carcinoma.